GSK PLC Sponsored ADR (NYSE:GSK) Stock Has Consensus Target Price of $55.33

Key Points

• Analyst consensus is “Hold”: Of 19 analysts covering GSK, 12 recommend holding, four recommend buying and three recommend selling. The average 12-month price target is $55.33 versus an opening price of $49.43.
• GSK exceeded quarterly expectations: The pharmaceutical company reported adjusted EPS of $1.36, beating estimates of $1.27, while revenue rose 5.3% year over year to $11.14 billion.
• Dividend increased: GSK raised its quarterly dividend to $0.4515, equivalent to $1.81 annually and a 3.7% yield, with a current payout ratio of 55.31%.

Shares of GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) have been given a consensus recommendation of "Hold" by the nineteen analysts that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $55.33.

Several analysts recently commented on GSK shares. Wolfe Research began coverage on shares of GSK in a research report on Friday, October 9th. They set an "outperform" rating and a $70.00 price target on the stock. HSBC reaffirmed a "hold" rating on shares of GSK in a report on Thursday, September 10th. JPMorgan Chase & Co. reiterated a "sell" rating on shares of GSK in a research report on Thursday, October 1st. Weiss Ratings lowered shares of GSK from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Wednesday, July 29th. Finally, Jefferies Financial Group restated a "buy" rating on shares of GSK in a research report on Monday, September 28th.

GSK Price Performance

Shares of NYSE GSK opened at $49.43 on Tuesday. The stock has a market capitalization of $99.99 billion, a price-to-earnings ratio of 15.46, a PEG ratio of 2.23 and a beta of 0.33. GSK has a 12 month low of $42.85 and a 12 month high of $61.69. The firm's 50 day simple moving average is $49.56 and its 200-day simple moving average is $51.58. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.02 billion. During the same period in the previous year, the firm earned $0.47 EPS. The business's quarterly revenue was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Analysts expect that GSK will post 4.78 EPS for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 8th. Investors of record on Friday, August 14th were issued a $0.4515 dividend. This represents a $1.81 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date of this dividend was Friday, August 14th. This is a positive change from GSK's previous quarterly dividend of $0.44. GSK's payout ratio is currently 55.31%.

Hedge Funds Weigh In On GSK

A number of hedge funds have recently bought and sold shares of GSK. NewEdge Advisors LLC boosted its holdings in GSK by 842.9% in the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company's stock worth $49,986,000 after buying an additional 852,437 shares during the last quarter. Sound Income Strategies LLC raised its holdings in shares of GSK by 2.7% during the third quarter. Sound Income Strategies LLC now owns 348,273 shares of the pharmaceutical company's stock valued at $16,209,000 after acquiring an additional 9,218 shares during the last quarter. Waverly Advisors LLC raised its holdings in shares of GSK by 1,372.8% during the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company's stock valued at $15,233,000 after acquiring an additional 270,863 shares during the last quarter. Tidal Investments LLC lifted its position in shares of GSK by 4.6% in the second quarter. Tidal Investments LLC now owns 220,236 shares of the pharmaceutical company's stock valued at $11,545,000 after acquiring an additional 9,603 shares in the last quarter. Finally, Keystone Financial Planning Inc. lifted its position in shares of GSK by 3,114.8% in the second quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company's stock valued at $10,253,000 after acquiring an additional 189,506 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

About GSK

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.